EBV: A hidden player
More and more people are suffering from persistent and largely unexplained symptoms (Fig. 1). The real causes are often undetected.
Do you also have a wide range of similar symptoms? Have you or your doctor ever considered the potential impact of the Epstein-Barr virus (EBV)?
Clinical experience of practitioners of micro-immunotherapy has shown that these manifestations are indicative of a reactivation of this virus. Therefore, in order to avoid multiple potential misdiagnoses, it is convenient to rule out diagnostically an EBV burden in these cases.
Sore throat and/or swollen cervical lymph nodes
Chronic malaise
Migratory joint and muscle pain
Severe fatigue
Unexplained temperature spikes
Fig. 1: Symptoms indicative of EBV reactivation
Furthermore, this virus, which is the most common cause of glandular fever (also known as mononucleosis), has also been associated with a wide range of different diseases (Fig. 2).
Glandular fever (mononucleosis)
Fibromyalgia and other pain disorders
Recurrent infections
Autoimmune diseases (including multiple sclerosis, Hashimoto, Lupus)
Chronic fatigue syndrome
Cancer (including Burkitt lymphoma, Hodgkin’s disease)
Fig. 2: Association between EBV and various diseases (a selection)
Micro-immunotherapy & EBV infections
Hence, it is important to detect EBV and treat it if a viral burden is confirmed, thereby positively influencing the course of the illness, and paving the way towards health. Since the immune system plays an important role in controlling the EBV infection, immunomodulatory treatments like micro-immunotherapy may be of great help.
The formula used to treat EBV infections is aimed at inhibiting virus replication and/or infection of other cells via a specific combination of immunomodulatory substances (including cytokines) and nucleic acids in low doses, thereby supporting the function of the immune system at the same time.
EBV & Long COVID
The symptoms of Epstein-Barr virus reactivation and Post-COVID / Long COVID syndrome are often overlapping. The results of a recent study showed that 73,3% of the surveyed post-COVID patients were undergoing an EBV reactivation, suggesting that various Long COVID symptoms may be associated with an EBV reactivation induced by COVID-19 inflammation. EBV may therefore be an important player in the onset and persistence of this clinical picture.
These findings open new perspectives for the diagnosis and treatment of persistent COVID-19 and point toward EBV detection and control strategies as a promising therapeutic approach in Long COVID patients. If an EBV reactivation is confirmed through serology, bringing the virus under control may be an essential step toward recovery.
Micro-immunotherapy, an immunoregulatory treatment that communicates with the immune system through immune messenger substances in low doses, can contribute to recovery by inhibiting Epstein-Barr virus replication and/or infection of further cells, promoting the antiviral immune response and preventing the onset of EBV-associated diseases.
If you would like to learn more on micro-immunotherapy as part of an integrated prevention and treatment plan in SARS-CoV-2 infections, register to our our professional area to check the Brochure on Micro-immunotherapy & Post-COVID syndrome or contact us directly at micro-immunotherapy@micro-immunotherapy.com
- Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation. Pathogens. 2021 Jun 17;10(6):763. doi: 10.3390/pathogens10060763.
MORE INFORMATION
